JMP Securities Reiterates Market Outperform on Iovance Biotherapeutics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Reni Benjamin has reiterated a Market Outperform rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a price target of $18.
September 15, 2023 | 12:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating on Iovance Biotherapeutics and maintained a price target of $18.
The reiteration of a Market Outperform rating by JMP Securities indicates a positive outlook for Iovance Biotherapeutics. The maintained price target of $18 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100